



Xenotransplantation: Targeting Acute Vascular Rejection and Endothelial Activation

Guest Editor:

Dr. Konrad Fischer

Chair of Livestock Biotechnology,
Technical University of Munich,
Freising, Germany

Deadline for manuscript
submissions:

closed (31 May 2024)

Message from the Guest Editor

Dear Colleagues,

Acute vascular rejection (AVR) still presents a major hurdle to long-term xenograft acceptance. Although several transgene combinations and knockouts have been described, xenografts are still undergoing AVR. New insights into innate and adaptive immune responses as well as detailed characterizations of signaling pathways are necessary to further optimize the pigs and protect the xenografts. In this Special Issue, we focus on the role of the endothelium during AVR, including the endothelial glycocalyx and underlying signaling pathways, and investigate new means of overcoming blood coagulation mechanisms and thrombotic microangiopathy (TMA).

Dr. Konrad Fischer
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)